MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Single-photon emission computed tomography(SPECT)"

  • 2026 International Congress

    fMRI Activity during Working Memory Manipulation is Associated with Caudate Integrity in Early Parkinson’s Disease

    K. Giehl, H. Theis, A. Asendorf, M. Banwinkler, V. Dzialas, R. Lubomierski, M. Hönig, T. van Eimeren (Juelich, Germany)

    Objective: This study aimed to determine whether reduced dopaminergic integrity and increased iron deposition in the caudate are associated with altered BOLD activation during high…
  • 2025 International Congress

    Brain perfusion patterns associated with motor symptoms in multiple system atrophy

    Y. Nakano, A. Sugiyama, S. Hirano, Y. Nakagawa, M. Tamura, T. Yamamoto, Y. Koizumi, Y. Suzuki, K. Yamagishi, Y. Chishiki, S. Kuwabara, Y. Kitayama (Chiba, Japan)

    Objective: There is a need for objective methods to assess disease progression in multiple system atrophy (MSA). This study aimed to identify brain perfusion patterns…
  • 2025 International Congress

    Cerebrospinal fluid DOPA decarboxylase levels as a marker of disease severity in Parkinson’s Disease

    K. Groenewald, L. van Hillegondsberg, T. Eisenstein, J. Klein, M. Hu (Oxford, United Kingdom)

    Objective: To assess the correlation of CSF DDC levels to DaT-SPECT SBR in PD and iRBD. Background: Raised cerebrospinal fluid (CSF) proteomic biomarker, DOPA decarboxylase…
  • 2025 International Congress

    Results From a Dose-Blinded, Phase II Extension Study Evaluating Long-Term Efficacy, Safety and Tolerability of Minzasolmin in Participants With Parkinson’s Disease

    C. Beuter, S. Carson, M. Key Prato, N. Massat, R. Maguire, A. Dhar Koul, E. Lucassen, J-M. Riethusien, I. Giunzioni, A. Pethe, G. Goethals, A. Khanna, Z. Ali (Monheim am Rhein, Germany)

    Objective: ORCHESTRA XT (PD0055; NCT05543252) was a Phase II, dose-blinded extension of the ORCHESTRA Phase II, proof-of-concept study (NCT04658186). ORCHESTRA XT assessed the pharmacodynamic effects of…
  • 2025 International Congress

    Identifying subjects at high risk for prodromal Parkinson’s Disease using dopamine transporter imaging deficit in a step-wise recruitment strategy: Data of Healthy Brain Ageing (HeBA)

    S. Schade, C. Corinne, S. Ghosh, A. Garrido, E. Lang, P. Mahlknecht, C. Pauly, D. Pilco, R. Rautenkranz, K. Rege, S. Scaglione, S. Schnell, T. Wicke, V. Satagopam, M. Marti, E. Tolosa, W. Poewe, R. Krüger, C. Trenkwalder, B. Mollenhauer (Kassel, Germany)

    Objective: To optimize screening for subjects with dopamine transporter (DaT) imaging deficit being at high risk for prodromal Parkinson's disease (PD). Background: Efficient screening methods…
  • 2025 International Congress

    A Prospective, Observational Study to Identify Biomarkers in Parkinsonian Syndromes (proATYP).

    M. Makrygianni, D. Potamianou, T. Pipikos, M. Xilouri, C. Mourmouris, A. Sarafi, L. Florentin, M. Stamelou (Athens, Greece)

    Objective: This is a prospective observational study to identify biomarkers in parkinsonian syndromes. Background: Parkinson’s disease (PD) and atypical parkinsonian syndromes namely progressive supranuclear palsy…
  • 2025 International Congress

    A multi-center, randomized, controlled study of the add-on effect of selegiline or zonisamide to L-dopa/DCI therapy in Parkinson’s disease (DATSZ-PD study)

    M. Takahashi, J. Koh, T. Shimokawa, Y. Kajimoto, T. Takeshima, H. Ito (Hirakata, Osaka, Japan)

    Objective: To investigate the efficacy and safety for neuroprotection and disease modifying effect in  selegiline(SL) or zonisamide(ZN) by using UPDRS, PDQ-39 and DAT -SPECT  in…
  • 2025 International Congress

    Dopamine Transporter Imaging as a Predictor of Functional Outcomes in Parkinson’s Disease

    K. Niemi, V. Kaasinen, J. Joutsa (Turku, Finland)

    Objective: To evaluate the prognostic value of dopamine transporter (DAT) imaging in predicting future disability, as well as motor and non-motor burden, in Parkinson’s disease…
  • 2025 International Congress

    Semi-quantitative Evaluation of Midbrain Accumulation in 123I-FP-CIT SPECT in Parkinson’s disease and Parkinsonian Syndromes

    T. Totsune, T. Baba, Y. Sugimura, H. Oizumi, H. Tanaka, T. Takahashi, M. Yoshioka, K. Nagamatsu, T. Hasegawa, A. Takeda (Sendai, Japan)

    Objective: To establish a method for evaluating midbrain accumulation of 123I-FP-CIT SPECT and assess its ability to differentiate between Parkinson’s disease (PD) and Parkinsonian syndromes…
  • 2025 International Congress

    Identifying Cut-off Values, Effects of AD Co-pathology, Sex Differences, and Temporal Changes of 123I-FP-CIT SPECT in Autopsy-proven LBD

    T. Miyagawa, S. Przybelski, C. Cynthia, HK. Minmin, L. Forsberg, J. Fields, S. Mccarter, T. Ferman, V. Ramanan, J. Graff-Radford, D. Jones, R. Savica, D. Knopman, R. Petersen, R. Reichard, A. Nguyen, D. Dickson, M. Murray, G. Day, N. Graff-Radford, C. Lachner, E. St Louis, M. Jain, K. Kantarci, V. Lowe, B. Boeve (ROCHESTER, USA)

    Objective: We analyzed autopsy-proven Lewy body disease (LBD) and/or Alzheimer’s disease (AD) dementia patients with 123I-FP-CIT SPECT to investigate previously unclarified detailed aspects of 123I-FP-CIT…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 16
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley